HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.

Abstract
Asthma is a disorder of the airways involving various inflammatory cells and mediators and characterised by bronchial hyperresponsiveness, chronic inflammation and structural alterations in the airways, also known as remodelling. IgE is an important mediator of allergic reactions and has a central role in allergic asthma pathophysiology, as it is implicated in both the early and late phase allergic response. Moreover, clinical and mechanistic evidence has lately emerged, implicating IgE in the development of airway remodelling. The use of monoclonal antibodies targeting IgE, such as omalizumab, has proven very effective in improving respiratory symptoms and quality of life, while reducing asthma exacerbations, emergency room visits and the use of systemic corticosteroids in allergic severe asthma. These effects are believed to be mainly mediated by omalizumab's inhibitory effect on the initiation and further propagation of the allergic inflammation cascade. However, there is evidence to suggest that anti-IgE treatment remains effective long after it has been discontinued. In part, these findings could be attributed to the possible ameliorating effects of anti-IgE treatment on airway remodelling. In this review, we discuss recent findings supporting the notion that anti-IgE treatment modulates the complex immune responses that manifest clinically as asthma and ameliorates airway remodelling changes often observed in allergic severe asthma phenotypes.
AuthorsKonstantinos Samitas, Vasiliki Delimpoura, Eleftherios Zervas, Mina Gaga
JournalEuropean respiratory review : an official journal of the European Respiratory Society (Eur Respir Rev) Vol. 24 Issue 138 Pg. 594-601 (Dec 2015) ISSN: 1600-0617 [Electronic] England
PMID26621973 (Publication Type: Journal Article, Review)
CopyrightCopyright ©ERS 2015.
Chemical References
  • Allergens
  • Anti-Allergic Agents
  • Anti-Asthmatic Agents
  • Anti-Inflammatory Agents
  • Biomarkers
  • Omalizumab
  • Immunoglobulin E
Topics
  • Airway Remodeling (drug effects)
  • Allergens (immunology)
  • Animals
  • Anti-Allergic Agents (adverse effects, therapeutic use)
  • Anti-Asthmatic Agents (adverse effects, therapeutic use)
  • Anti-Inflammatory Agents (adverse effects, therapeutic use)
  • Asthma (diagnosis, drug therapy, immunology, physiopathology)
  • Biomarkers (blood)
  • Humans
  • Immunoglobulin E (blood, immunology)
  • Lung (drug effects, immunology, physiopathology)
  • Omalizumab (adverse effects, therapeutic use)
  • Phenotype
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: